entertainment -WSS

entertainment

author：knowledge 2025-09-30 22:04:14 - browse：83

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Flagship, Pfizer team up in deal worth up to $7 billion

WSS

AdventHealth escalates lawsuit against insurance vendor Multiplan

Twill hunts for pharma partner to market its depression app

Federal weight loss drug coverage is 30 years out of date

3 trends to watch in health tech's hiring outlook for 2024

Study: Hearing aids may slow cognitive decline in those at risk

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

At least 13 dead in Texas as scorching temps continue

Videos point to link between seizures and unexplained toddler deaths

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Chronically ill young patients struggle to find fertility info

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Federal weight loss drug coverage is 30 years out of date

Malaria cases in Florida and Texas: Here’s what you need to know

Study: Hearing aids may slow cognitive decline in those at risk

Sports medicine is finally prioritizing gender equality

U.K. sequencing study surfaces new findings about tumor DNA

focus

AdventHealth escalates lawsuit against insurance vendor Multiplan

Morgan Health, with ambitious aims, wants you to know it’s still here

More hospitals are billing patients as online messages surge

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

White House finalizes ITC's import ban of latest Apple Watches

Ahead of JPM, here's who's profiting most in health care

focus

focus

explore

knowledge